Jump to content

Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > generic: None

& classes

: Dissociative

or the first approved

Use the filters below to narrow your results.

Belsomra (1) · Spravato (1)

None (1) · Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant. (1)

Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease. (1) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)

10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned) (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)

28 mg/device (each dose uses 2 devices) (1) · 5 mg, 10 mg, 15 mg, 20 mg tablets (1)

20 mg/d (1) · 84 mg per session (1)

Intranasal (under direct medical supervision) (1) · Oral (1)

Within hours of first administration (1) · ~30 min (1)

Acute effect ~24 hours; cumulative effect builds with repeated dosing (1) · ~7-8 hours (1)

~12 hours (1) · ~7-12 hours (1)

~48% intranasal (1) · ~82% (1)

Avoid; may cause fetal harm (1) · Limited data; avoid (1)

Rx, Schedule III (US). REMS program required. (1) · Rx, Schedule IV (US) (1)

Showing below up to 2 results in range #1 to #2.

E

Esketamine

S

Suvorexant

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"